BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year High – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $16.85 and last traded at $16.0640, with a volume of 317585 shares changing hands. The stock had previously closed at $14.03.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BIOA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Citigroup boosted their price objective on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioAge Labs currently has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Stock Performance

The business has a 50 day moving average of $10.90. The firm has a market capitalization of $619.85 million, a price-to-earnings ratio of -11.53 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

Insider Buying and Selling

In other BioAge Labs news, insider Paul D. Rubin sold 18,000 shares of BioAge Labs stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

Several large investors have recently made changes to their positions in BIOA. Russell Investments Group Ltd. acquired a new position in BioAge Labs during the 3rd quarter worth approximately $27,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of BioAge Labs during the second quarter valued at approximately $27,000. Bank of America Corp DE lifted its holdings in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after purchasing an additional 3,517 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in BioAge Labs during the 2nd quarter valued at $57,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.